（一） 股东大会召开的时间：2024 年 5 月 21 日 （二） 股东大会召开的地点：上海市浦东新区琥珀路 63 弄 1 号 M08 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 证券代码：688265 证券简称：南模生物 公告编号：2024-025 上海南方模式生物科技股份有限公司 2023 年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 11 | | --- | --- | | 普通股股东人数 | 11 | | 2、出席会议的股东所持有的表决权数量 | 51,147,888 | | 普通股股东所持有表决权数量 | 51,147,888 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 66.6654 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 66.6654 | ...

上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海南方模式生物科技股份有限公司 2023 年年度股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海南方模式生物科技股份有限公司 2023年年度股东大会的 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务管 理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行了法 定职责，遵循了勤勉尽责和诚实信用原则，对本次股东大会所涉及的相关事项进行 了必要的核查和验证，核查了本所认为出具该法律意见书所需的相关文件、资料， 并参加了公司本次股东大会的全过程。本所保证本法律意见书所认定的事实真实、 准确、完整，所发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者 重大遗漏，并愿意承担相应法律责任。 本法律意见书仅供本次股东大会之目的使用。本所律师同意将本法律意见书 随南模生物本次股东大会其他信息披露资料一并公告。 鉴此，本所 ...

（网址：http://roadshow.sseinfo.com/） 证券代码：688265 证券简称：南模生物 公告编号：2024-024 上海南方模式生物科技股份有限公司 关于参加 2023 年度生物制品专场集体业绩说明会 暨 2024 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司已于 2024 年 4 月 30 日发布公司《2023 年年度报告》《2024 年第一季 度报告》，为便于广大投资者更全面深入地了解公司 2023 年度和 2024 年第一季 度经营成果、财务状况，公司参加了由上海证券交易所主办的 2023 年度生物制 品专场集体业绩说明会，此次活动将采用网络文字互动的方式举行，欢迎广大投 资者积极参与。公司现就 2023 年度生物制品专场集体业绩说明会暨 2024 年第一 季度业绩说明会提前向广大投资者征集相关问题，广泛听取投资者的意见和建议。 一、说明会类型 本次业绩说明会以网络文字互动形式召开，公司将针对 2023 年度和 2024 年 第一季度的经营成 ...

海通证券股份有限公司 关于上海南方模式生物科技股份有限公司 2023 年度持续督导年度跟踪报告 | | 技股份有限公司 | | --- | --- | | 保荐机构名称：海通证券股份有限公司 保荐代表人姓名：张子慧、陈亚聪 | 被保荐公司简称：上海南方模式生物科 被保荐公司代码：688265 | 经中国证券监督管理委员会（证监许可〔2021〕3469 号）批复，上海南方模 式生物科技股份有限公司（以下简称"南模生物"、"上市公司"、"公司"或"发行 人"）首次公开发行股票 1,949.0900 万股，每股面值人民币 1 元，每股发行价格 人民币 84.62 元，募集资金总额为人民币 1,649,319,958.00 元，扣除发行费用后， 实际募集资金净额为人民币 1,467,876,199.92 元。本次发行证券已于 2021 年 12 月 28 日在上海证券交易所上市。海通证券股份有限公司（以下简称"保荐机构" 或"海通证券"）担任其持续督导保荐机构，持续督导期间为 2021 年 12 月 28 日至 2024 年 12 月 31 日。 在 2023 年 1 月 1 日至 2023 年 12 月 31 日持 ...

海通证券股份有限公司 关于上海南方模式生物科技股份有限公司 2023 年度持续督导现场检查报告 上海证券交易所： 经中国证券监督管理委员会（证监许可〔2021〕3469 号）批复，上海南方模 式生物科技股份有限公司（以下简称"南模生物"、"上市公司"、"公司"或"发行 人"）首次公开发行股票 1,949.0900 万股，每股面值人民币 1 元，每股发行价格 人民币 84.62 元，募集资金总额为人民币 1,649,319,958.00 元，扣除发行费用后， 实际募集资金净额为人民币 1,467,876,199.92 元。本次发行证券已于 2021 年 12 月 28 日在上海证券交易所上市。海通证券股份有限公司（以下简称"保荐机构" 或"海通证券"）担任其持续督导保荐机构，持续督导期间为 2021 年 12 月 28 日至 2024 年 12 月 31 日。 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》《上海证券交易所上市公司自律监管指引第 11 号——持续督导》《上海 证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关法律、法 规要求，海通证券作为持续督导保荐机 ...

证券代码：688265 证券简称：南模生物 公告编号：2024-023 上海南方模式生物科技股份有限公司 2024 年 4 月，公司通过上海证券交易所交易系统以集中竞价交易方式回购公 司股份 250,001 股，占公司总股本 77,963,513 股的比例为 0.3207%，回购成交的最 高价为 27.38 元/股，最低价为 23.90 元/股，支付的资金总额为人民币 648.9317 万 元（不含税费、交易佣金等交易费用）。 重要内容提示： | 回购方案首次披露日 | 2024/2/24 | | --- | --- | | 回购方案实施期限 | 2024/2/23~2024/5/22 | | 预计回购金额 | 1,500 万元~3,000 万元 | | 回购用途 | □减少注册资本 □用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | √为维护公司价值及股东权益 | | 累计已回购股数 | 78.8912 万股 | | 累计已回购股数占总股本比例 | 1.0119% | | 累计已回购金额 | 2,145.3359 万元 | | 实际回购价格区间 | 23.90 元/股~29.98 元 ...

2024 年 4 月 上海南方模式生物科技股份有限公司 模式动物是实验动物的一个重要分支，能够模仿人类疾病的各个方面，帮助 科研人员获得有关疾病及其预防、诊断和治疗的资料，因此被广泛应用于生物分 析、表型分析以及药效分析与评价等领域。模式动物包括众多种类，如鼠类、猴 类、犬类等，其中小鼠的应用最为广泛。鼠类模型具有繁殖能力强、世代周期短； 组织器官结构和细胞功能结构与人类相似；与人类基因高度同源，且已完成全基 1 因组测序的优势，常应用于科学探索和药物开发，为应用最广泛的模式动物。基 因修饰动物指利用各种基因编辑技术把模式动物中目的 DNA 片段导入或删除， 实现内源基因的修改，从而构造出能够模拟人类特定生理、病理、细胞特征的生 物模型，多用于靶点研究与药效评估。相较其他类别动物模型，基因修饰动物模 型可以实现对人类生理或病理更精确的模拟，更适合作为研究人类基因功能和疾 病致病机制探索的实验模型；当前大量学术研究、药物开发围绕靶点进行，基因 修饰动物契合了这一研发潮流。 南模生物成立于 2000 年，作为国内较早从事基因修饰动物模型业务的公司 之一，深耕基因修饰动物模型市场多年，始终以研发创新为驱动，核心技术 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of $500 million for the fiscal year, representing a 25% year-over-year growth [200]. - The company's operating revenue for 2023 reached ¥366,548,781.43, representing a year-on-year increase of 20.99% compared to ¥302,965,239.57 in 2022 [23]. - The net profit attributable to shareholders of the listed company was -¥20,582,607.05, a decline of 281.18% from -¥5,399,643.49 in the previous year [26]. - The net profit attributable to the parent company was approximately -20.58 million yuan, a year-on-year decline of 281.18% [37]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was approximately -39.51 million yuan, a year-on-year decrease of 33.67% [37]. - The gross margin improved to 60%, up from 55% in the previous year, indicating better cost management [15]. - The company's total assets at the end of 2023 were ¥1,997,768,441.18, down 2.72% from ¥2,053,677,965.52 in 2022 [23]. - The company's total production capacity at the end of the reporting period was approximately 140,000 cage positions, with a year-on-year optimization in cage utilization rates across various bases [42]. Research and Development - The company is investing $10 million in R&D for new therapeutic solutions aimed at rare diseases [15]. - Research and development expenses accounted for 21.89% of operating revenue, an increase of 0.19 percentage points from 21.70% in 2022 [25]. - The total R&D expenditure for the year was approximately ¥80.24 million, an increase of 22.02% compared to the previous year, with R&D expenses accounting for 21.89% of total revenue [95]. - The company has developed over 18,000 models, with more than 11,000 standardized models and provided over 7,500 customized models to clients [38]. - The company is focusing on continuous R&D of gene editing technology and gene-modified animal models, leveraging advanced technology and services in the life sciences and biomedicine sectors [59]. - The company has established a comprehensive drug efficacy evaluation service using genetically modified animal models, covering major human diseases [107]. - The company aims to enhance gene editing technology to improve target gene editing success rates and reduce off-target risks [176]. Market Expansion and Strategy - The company is expanding its market presence in Europe, targeting a 15% market share by the end of the next fiscal year [15]. - The company plans to expand its overseas business development team, particularly in biopharmaceutical hubs like Boston and California, to enhance market penetration [46]. - The company is committed to deepening domestic market penetration while expanding its global presence, particularly in Europe and the United States [182]. - The company is exploring partnerships with key industry players to enhance distribution channels and expand reach [199]. - The company plans to enhance its digital platform, aiming for a 40% increase in user engagement metrics [15]. - The company is expanding its marketing network by enhancing collaboration among sales, business, and technical support departments, and increasing brand exposure through events and new media operations [188]. Governance and Compliance - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants [6]. - The company has confirmed that all board members attended the board meeting, ensuring governance compliance [6]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties [8]. - The company has not experienced any violations of decision-making procedures regarding external guarantees [8]. - The company has not disclosed any special arrangements for corporate governance [8]. Risks and Challenges - The company has outlined potential risks in its operations, which are detailed in the "Management Discussion and Analysis" section of the report [5]. - The company emphasizes the importance of understanding the risks associated with forward-looking statements regarding future plans and strategies [7]. - The company faced increased production costs due to new facilities and rising expenses, impacting profitability [26]. - The company is exposed to competition from both domestic and international firms in the genetically modified animal model industry, which could impact its market expansion efforts [118]. - The company may face risks related to regulatory compliance as the industry is subject to increasing scrutiny regarding animal welfare and ethical standards [127]. Investments and Acquisitions - A strategic acquisition of a smaller biotech firm was completed, which is anticipated to add $50 million in annual revenue [15]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of $100 million allocated for this purpose [200]. - The company has made private equity investments totaling 11,500,000 RMB, with a reported loss of 152.48 RMB during the period [169]. Customer and Sales Performance - User data showed an increase in active users, reaching 1.2 million, which is a 30% increase compared to the previous year [15]. - The company signed new orders worth 377 million yuan during the reporting period, reflecting a growth rate of 13.55% [49]. - The company has established sales in nearly 20 countries, including the United States, Germany, Japan, South Korea, and the United Kingdom [46]. - Customized model revenue increased by 64.75% year-on-year, while standardized model revenue grew by 34.03% [48]. Future Outlook - The company provided guidance for the next fiscal year, projecting revenue growth of 20% to $600 million [15]. - The company aims to enhance investment and financing efficiency, broadening external financing channels and improving the efficiency of raised funds to support sustainable and high-quality development [183]. - The company aims to become a leader in the genetically modified model organism industry, contributing to advancements in biomedicine and improving human health [177].

Financial Performance - The company's operating revenue for Q1 2024 was ¥82,932,302.56, representing a decrease of 5.01% compared to the same period last year[4] - Total operating revenue for Q1 2024 was ¥82,932,302.56, a decrease of 5.3% compared to ¥87,304,768.91 in Q1 2023[18] - The net profit attributable to shareholders was -¥12,897,060.70, with a net profit excluding non-recurring items of -¥18,517,804.80[4] - Net loss for Q1 2024 was ¥12,897,060.70, an improvement from a net loss of ¥14,231,619.55 in Q1 2023, indicating a 9.4% reduction in losses[19] - The company's total assets decreased to ¥1,953,324,217.74 in Q1 2024 from ¥1,997,768,441.18 in Q1 2023, a decline of 2.2%[17] - Total liabilities decreased to ¥244,050,810.79 in Q1 2024 from ¥260,985,055.13 in Q1 2023, representing a reduction of 6.5%[17] - The company's total equity attributable to shareholders decreased to ¥1,709,273,406.95 in Q1 2024 from ¥1,736,783,386.05 in Q1 2023, a decline of 1.6%[17] - The basic and diluted earnings per share for Q1 2024 were both -¥0.17, compared to -¥0.18 in Q1 2023, reflecting a slight improvement[19] Cash Flow - The net cash flow from operating activities was -¥28,394,359.82, indicating a significant cash outflow[4] - In Q1 2024, the company's cash inflow from operating activities was CNY 67,757,018.71, compared to CNY 66,448,951.40 in Q1 2023, reflecting a slight increase of 1.96%[22] - The net cash outflow from operating activities improved to CNY -28,394,359.82 in Q1 2024 from CNY -33,872,953.18 in Q1 2023, indicating a reduction in losses by approximately 16.5%[22] - Cash inflow from investment activities totaled CNY 296,496,310.15 in Q1 2024, down from CNY 885,839,718.79 in Q1 2023, representing a decrease of 66.5%[23] - The net cash flow from investment activities was CNY 60,121,373.98 in Q1 2024, compared to CNY 31,629,037.84 in Q1 2023, showing an increase of 90.2%[23] - The company reported a cash outflow from financing activities of CNY 20,983,339.83 in Q1 2024, significantly higher than CNY 6,364,701.52 in Q1 2023, marking an increase of 229.5%[23] - The net increase in cash and cash equivalents for Q1 2024 was CNY 10,740,267.10, contrasting with a decrease of CNY -8,743,172.73 in Q1 2023[23] - The ending balance of cash and cash equivalents rose to CNY 108,343,188.50 in Q1 2024 from CNY 358,699,458.77 in Q1 2023, indicating a decrease of 69.8% year-over-year[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,953,324,217.74, down 2.22% from the end of the previous year[5] - The total current assets as of March 31, 2024, amounted to ¥108,343,188.50, an increase from ¥97,602,921.40 as of December 31, 2023, reflecting a growth of approximately 10.8%[15] - The trading financial assets decreased to ¥866,319,453.74 from ¥927,284,641.17, representing a decline of about 6.6%[15] - Accounts receivable increased to ¥128,010,514.23 from ¥108,035,604.85, indicating a rise of approximately 18.5%[15] - Inventory rose to ¥16,853,575.55 compared to ¥15,828,142.53, showing an increase of about 6.4%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 6,753[9] - The top shareholder, Shanghai Dish Enterprises Management Consulting Co., Ltd., holds 27,771,000 shares, representing 35.62% of total shares[9] - The number of shares held by the top 10 shareholders includes Shanghai Technology Venture Capital Co., Ltd. with 10,576,333 shares, representing 13.57% of total shares[13] - Shanghai Pudong New Emerging Industry Investment Co., Ltd. holds 2,160,000 shares, accounting for 2.77% of total shares[13] - The company has not reported any significant changes in the shareholder structure due to margin trading activities[13] - The total number of shares repurchased by the company as of the report date is 990,229 shares[11] Research and Development - Research and development expenses totaled ¥19,334,427.95, accounting for 23.31% of operating revenue, an increase of 0.63 percentage points year-on-year[5] - Research and development expenses for Q1 2024 were ¥19,334,427.95, slightly down from ¥19,799,024.04 in Q1 2023, showing a decrease of 2.3%[18] - The company has not disclosed any new product developments or technological advancements in this quarter[15] Mergers and Acquisitions - There are no significant mergers or acquisitions reported during this period[15] Audit Information - The company did not conduct an audit for the Q1 financial statements[4] Profitability - The company reported non-recurring gains of ¥5,620,744.10 for the period, primarily from government subsidies and financial asset valuations[6][7] - The company reported a gross profit margin of approximately 43.4% for Q1 2024, compared to 40.0% in Q1 2023, indicating an improvement in profitability[18] - The weighted average return on net assets was -0.75%, an increase of 0.07 percentage points[5]

证券代码：688265 证券简称：南模生物 公告编号：2024-011 上海南方模式生物科技股份有限公司 关于以集中竞价交易方式回购股份进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海南方模式生物科技股份有限公司（以下简称"公司"）截至 2024 年 3 月 31 日，通过上海证券交易所交易系统以集中竞价交易方式回购公司股份 538,911 股，占公司总股本 77,963,513 股的比例为 0.6912%，回购成交的最 高价为 29.98 元/股，最低价为 26.03 元/股，支付的资金总额为人民币 1,496.4042 万元（不含税费、交易佣金等交易费用）。 2024 年 3 月，公司通过上海证券交易所交易系统以集中竞价交易方式回购 公司股份 509,654 股，占公司总股本 77,963,513 股的比例为 0.6537%，回购成交 的最高价为 29.98 元/股，最低价为 26.03 元/股，支付的资金总额为人民币 1,416.7307 万元（不含税费、交易佣金等交易费用）。 截至 ...